Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
LENZ Therapeutics, Inc. - Common Stock
(NQ:
LENZ
)
32.53
UNCHANGED
Streaming Delayed Price
Updated: 1:00 PM EDT, Jul 3, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about LENZ Therapeutics, Inc. - Common Stock
< Previous
1
2
Next >
ICC Holdings, Diamond Offshore Drilling, CrowdStrike And Other Big Stocks Moving Higher On Monday
June 10, 2024
Via
Benzinga
LENZ Therapeutics to Host Key Opinion Leader Event on June 18, 2024
June 10, 2024
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
LENZ Therapeutics to Present at the Jefferies Global Healthcare Conference
May 30, 2024
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
May 08, 2024
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
LENZ Therapeutics to Report First Quarter Financial Results and Business Update on May 8, 2024
May 01, 2024
From
Lenz Therapeutics, Inc.
Via
GlobeNewswire
Blindness-Focused LENZ Therapeutics' Investigational Eye Drop Ready To Revolutionize Presbyopia Landscape, Analyst Says
April 10, 2024
Advances in presbyopia treatment with LENZ Therapeutics' LNZ100. Clinically proven to enhance near-vision for up to 10 hours, it offers a promising alternative to reading glasses. Analysts predict a...
Via
Benzinga
Newly Listed Lenz Therapeutics' Vision Loss Experimental Drug Meets Primary Goal In Late-Stage Study
April 03, 2024
LENZ Therapeutics unveils Phase 3 CLARITY study results on aceclidine formulations, LNZ100 & LNZ101. LNZ100 demonstrates significant improvement in Presbyopia, achieving primary and key secondary...
Via
Benzinga
LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials
April 03, 2024
From
LENZ Therapeutics, Inc.
Via
Business Wire
LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia Trials
April 02, 2024
From
LENZ Therapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
March 29, 2024
Via
Benzinga
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.